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What This Study Adds to the Field: This study demonstrates that the majority of platelet 
transfusions prescribed in the pediatric intensive care unit are given prophylactically to non-
bleeding children. The targeted thresholds in platelet count were heterogeneous. 
ABSTRACT 
Rationale: The epidemiology, indications, and outcomes for critically ill children transfused red 
blood cells or plasma have been described recently in large multicenter studies. This information 
is not known regarding platelet transfusions in this population.  
Objectives: To describe the epidemiology, indications, and outcomes of platelet transfusions 
among critically ill children. 
Methods: This point-prevalence study was conducted in 82 pediatric intensive care units in 16 
countries during six assigned weeks. All children included received a platelet transfusion 
prescribed during one of the screening days. 
Measurements and Main Results: During six weeks of screening, 16,934 patients were eligible, 
of whom 559 received at least one platelet transfusion (prevalence 3.3%).  The indications for 
transfusion included prophylaxis in 67%, minor bleeding in 21% and major bleeding in 12%. 
Thirty-four percent of prophylactic platelet transfusions were prescribed when the platelet count 
was ≥ 50 x 109 cells/L. The median (IQR) change in platelet count was 48 x 109 cells/L (17-82) 
for major bleeding, 42 x 109 cells/L (16-80) for prophylactic transfusions, 38 x 109 cells/L (17-
72) for minor bleeding, and 25 x 109 cells/L (10-47) for prophylaxis in patients at risk of 
bleeding from a device. Overall mortality for all patients was 25%. 
Conclusions: The majority of platelet transfusions prescribed are given as prophylaxis to non-
bleeding children and significant variation in platelet thresholds exists. Studies are needed to 
clarify appropriate indications, with a particular focus on prophylactic transfusions. 
Abstract: 234 words 
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INTRODUCTION 
Platelet transfusions are commonly prescribed in critical illness but uncertainty remains 
regarding their efficacy and safety for all indications. Platelet units are transfused to either 
prevent or reduce the risk of bleeding (considered “prophylactic transfusion”), or to treat 
clinically significant bleeding secondary to platelet dysfunction, thrombocytopenia or 
empirically with life-threatening bleeding (considered “therapeutic transfusion”). In 2015, an 
AABB survey reported that 48,000 children in the United States received 165,000 apheresis 
platelet units.1 Unfortunately, there is no information in these surveys or in large multicenter 
studies regarding the epidemiology, indications, and outcomes for critically ill children receiving 
platelet transfusions.  
Evidence-based guidelines for platelet transfusions administered to children are generally 
lacking. The current guidelines from the AABB are based primarily on expert opinion. 
Recommendations combine neonates (<1 month of age) with children (1 month to 18 years of 
age) and state that platelet transfusions are indicated for children: 1) with a total platelet count of 
< 10 x 109 cells/L due to hypoproliferative thrombocytopenia, 2) with active bleeding in 
association with a qualitative platelet defect, 3) with unexplained excessive bleeding in patients 
undergoing cardiopulmonary bypass or 4) undergoing extracorporeal membrane oxygenation 
(ECMO) with a total platelet count of < 100 x 109 cells/L.2  
Little is known about the practice of platelet transfusion in pediatric critical illness. In 
order to develop interventional studies to evaluate platelet transfusion strategies in critically ill 
children and to eventually guide platelet transfusion practices, it is important to know the 
epidemiology, indications, and outcomes in this population. The primary objective of the study 
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was to describe the patterns of platelet transfusions among critically ill children, including 
transfusion thresholds, indications, post transfusion platelet count increment, and outcomes.  
 
METHODS 
Study Population 
This point prevalence study was an international, prospective, cross-sectional design. 
Sites were recruited through the Pediatric Critical Care Blood Research Network (Blood Net), 
the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) network, the Canadian 
Critical Care Trials Group (CCCTG), the Australia and New Zealand Intensive Care Society 
(ANZICS), the Paediatric Intensive Care Society (UK), the Israeli Society of Pediatric Intensive 
Care, and sites who previously participated in a published point prevalence study on plasma 
transfusions (PlasmaTV).3 Each site was assigned six random weeks (between September 2016 
to April 2017) during which they screened subjects for eligibility and enrollment. A child was 
considered eligible if he/she was admitted to the pediatric intensive care unit during one of the 
seven screening days of the assigned week and was between 3 days and 16 years old. He/she was 
enrolled if he/she received a platelet transfusion prescribed by the intensive care medical team 
during one of the screening days. Patients were excluded if life expectancy was considered to be 
less than 24 hours, gestational age of the patient was less than 37 weeks at the time of admission, 
or the patient was enrolled in a previous screening week. The study was approved by the 
Institutional/Ethical Review Board at each individual participating site, except for the UK in 
which the study was approved by the Health Research Authority of the National Health Service. 
Waiver of consent was granted at all sites except one site in Italy that required written consent 
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for participation. Sites in Switzerland required a description of the study to be posted in the 
waiting room with an opt-out possibility for families. 
 
Data Collection 
 For each enrolled subject, the site chose from the following list of indications for 
transfusion (more than one indication could be selected): (1) total platelet count < 10 x 109 
cells/L with failure of platelet production; (2) total platelet count < 30 x 109 cells/L in neonate 
with failure of platelet production; (3) major bleeding: as defined by (a) bleeding that requires 
massive transfusion; (b) bleeding in specific sites: intracranial, intraocular, retroperitoneal, intra-
spinal, or non-traumatic intra-articular; or (c) bleeding requiring a surgical intervention of 
drainage (i.e. hemothorax requiring drainage); (4) minor bleeding (surgical or non-surgical): as 
defined by any bleeding that does not meet the above criteria for major bleeding; (5) preparation 
for surgery; (6) preparation for invasive procedure; (7) known qualitative platelet defect with risk 
of bleeding; (8) at risk of bleeding from device (ECMO, Ventricular Assist Device (VAD), 
other) or (9) other. Indications 1, 2, 5, 6, and 7 were all categorized as “prophylactic” 
transfusions.    
Data collected included patient demographics, reason for admission, any prior platelet 
transfusions during the current ICU admission, information regarding the platelet product, the 
transfusion event itself and any adverse reactions, as well as assays of total platelet count and 
function assessed before and after the platelet transfusion. All lab data was collected up to 36 
hours following the platelet transfusion of interest. Outcome data, including length of stay, 
length of mechanical ventilation and mortality, as well as severity of disease, as measured by 
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PELOD-2 score, were also collected. Study data were collected and managed using REDCap 
electronic data capture tools hosted at Weill Cornell Medical College. 
 
Statistical Approach 
Demographic and clinical characteristics were described as N (%) or mean +/- standard 
deviation (SD) or median and interquartile range (IQR) as appropriate.  Categorical data were 
compared by Fisher’s Exact/Chi-square tests. Continuous variables were compared by 
ANOVA/Kruskal-Wallis tests or t-test/Wilcoxon Rank Sum for parametric /non-parametric data, 
respectively. 95% confidence intervals were constructed for estimates of interest to analyze 
precision. All p-values were two-sided with statistical significance evaluated at the 0.05 alpha 
level. All analyses were performed in R version 3.4.0 (R Foundation for Statistical Computing, 
Vienna, Austria). 
 
RESULTS 
Prevalence 
Eighty two sites from sixteen countries contributed data. The majority of sites were urban 
(97%), academic (98%), trauma centers (85%) and ECMO centers (80%). Of the participating 
sites, 48 (58%) were located in North America, 23 (28%) in Europe, 4 (5%) in Oceania, 4 (5%) 
in the Middle East and 3 (4%) in Asia.  
 During the six weeks of screening, 16,934 patients were eligible, constituting an average 
of 13.6 eligible patients in each participating site at the start of the screening week. Of those, 559 
received platelet transfusions and were enrolled for a transfusion prevalence of 3.3%. On 
average, each individual institution enrolled 4% of eligible patients (95% CI 0-8.3).There were 9 
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sites (11%) who did not transfuse platelets during the entire study period and hence, did not 
enroll any subjects.  
 
Subjects 
 Subject demographics are summarized in Table 1 and categorized according to indication 
for platelet transfusion including major bleeding, minor bleeding, at risk of bleeding due to 
device, or prophylactic transfusion. The median (IQR) age of the subjects was 4.1 years (0.5 -
10.8) and 55% were male. The three most common reasons for admission were respiratory 
insufficiency/failure (39.2%), septic shock (22.4%) and cardiac surgery involving bypass 
(12.1%). Nearly half of the subjects (43.5%) had an underlying oncologic diagnosis. The 
majority of subjects were mechanically ventilated (64.4%) and admitted to the PICU for a 
median length of 2 days (IQR 2-7) before enrollment. The median PELOD-2 score at enrollment 
was 7 (IQR 5-10). The frequency of subjects receiving medications that affect platelet function 
was: milrinone (17.2%), aspirin (2.6%) and non-steroidal anti-inflammatories (2.2%). The 
frequency of subjects requiring the following interventions at the time of platelet transfusion 
was: extracorporeal life support (16.8%), continuous renal replacement therapy (10.6%), 
intermittent hemodialysis (1.3%), and molecular adsorbent recirculation system (0.9%). 
Approximately one-third (36%) of the children had received at least one other platelet 
transfusion in the PICU during the admission prior to enrollment in the study.  
 
Indications 
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 The indications for each platelet transfusion are summarized in Figure 1. Of note, the 
majority of transfusions were prophylactic; major or minor bleeding was the indication in only 
one-third of transfusions (33%).  
 
Transfusion 
 The majority of the platelets transfused were collected by apheresis (87.1%) versus whole 
blood derived (12.9%). The transfusions were commonly leukoreduced (93.4%), and irradiated 
(79.9%). They were infrequently volume reduced (8.3%), pathogen inactivated (4.5%) by 
INTERCEPT™ blood system, or HLA-matched (0.8%). The median platelet dose per 
transfusion event was 9.4 mL/kg (IQR 5.5-13.1). Subjects received a median 4 (IQR 2-11) 
platelet transfusion events during their PICU course for a total median dose of 32.4 mL/kg (IQR 
14.0-91.4). 
 Reported adverse reactions to the platelet transfusion were uncommon. A new fever or 
increase in temperature by 1°C, if already febrile, occurred most frequently (3.0%), followed by 
hypotension (2.6%), urticaria (0.6%), and bronchospasm (0.2%). There were no hemolytic 
reactions and no confirmed septic reactions. 
 
Laboratory Assays 
 The total platelet count was known within 24 hours prior to transfusion in the vast 
majority of cases (99.1%). The median (IQR) platelet count prior to transfusion was 40 x 109 
cells/L (20-66). Thirty-four percent of transfusions were prescribed when the platelet count was 
≥ 50 x 109 cells/L. For those children with an underlying oncologic diagnosis, the median (IQR) 
platelet count prior to transfusion was 25 x 109 cells/L (15-41) and for those supported by 
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ECMO, it was 70 x 109 cells/L (52-90). Viscoelastic testing, such as thromboelastography (TEG) 
and rotational thromboelastometry (ROTEM) were rarely analyzed prior to the transfusion (4.5% 
and 2.2% respectively). Other measures of platelet function, including response to P2Y12 
inhibitors (VerifyNow, Accriva Diagnostics, San Diego, CA, USA), PFA-100, and impedence 
aggregometry were each only assessed once (0.2%) prior to transfusion. 
 Figure 2 depicts the change in total platelet count following transfusion at various times 
and for various platelet indications corrected for transfusion dose. The median change in platelet 
count varied across groups based on indication (p=0.03). For every 10 mL/kg of platelets 
transfused, the median (IQR) change in platelet count was 48 x 109 cells/L (17-82) for patients 
with major bleeding, 42 x 109 cells/L (16-80) for prophylactic transfusions, 38 x 109 cells/L (17-
72) for patients with minor bleeding, and 25 x 109 cells/L (10-47) for patients at risk of bleeding 
from a device. The incremental change in platelet count did not vary between those who had an 
underlying oncologic diagnosis and those who did not (p=0.57). 
 
Outcomes 
  The median length of stay in the PICU was 13 days (6-29) with patients being 
mechanically ventilated a median length of 7 days (0-19). The mortality rate for all children 
analyzed was 25%. The outcomes based on indication are summarized in Table 2. 
 
 
DISCUSSION 
This international point prevalence study is the first published analysis of the 
epidemiology, indications, and outcomes in critically ill children transfused with platelets. 
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Approximately two–thirds of platelet transfusions were prescribed in a prophylactic manner to 
non-bleeding children. Thirty-four percent of prophylactic transfusions were prescribed when the 
platelet count was ≥ 50 x 109 cells/L. While the observed rise in the platelet count following 
transfusion varied based on indication, those at risk of bleeding from a device had the smallest 
increase. Mortality in patients who receive platelet transfusions was high, ranging from 17-35% 
according to indication.  
Platelet transfusion practices observed in this study resemble those published in adults. In 
one large observational study in critically ill adults in the UK, wide variation in platelet use was 
reported.4 The prevalence of platelet transfusion was reported to be 9%. More than half of 
platelet units were given as “prophylactic transfusions” in patients with no documented clinically 
significant bleeding. One-third of these transfusions were given to critically ill adults with a total 
platelet count > 50 x 109 cells/L. Similar findings were reported in a retrospective study from 3 
adult ICUs in Canada; platelet transfusions were commonly prescribed when the platelet count 
was ≥ 50 × 109 cells/L.5  The median platelet count reported prior to platelet transfusion was 87 x 
109 cells/L.  In these same two studies, the increment in total platelet count following transfusion 
was modest, 18.5 ± 30.4 x 109 cells/L and 23 × 109 cells/L.4,5  
Pediatric data from one single center prospective study reported the prevalence of 
critically ill children receiving at least one platelet transfusion to be 7.2%. The average platelet 
count was 49 ± 34 × 109 cells/L prior to transfusion, similar to thresholds reported in this study.4 
They report a wide range of incremental changes in platelet count following transfusion (from 30 
to nearly 100 x 109 cells/L), based on the indication for the transfusion. The incremental change 
in platelet count in critically ill children following platelet transfusion may be higher than that 
observed in critically ill adults because of better ABO compatibility, which has been implicated 
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in improved post-transfusion platelet increment in adults with hematologic malignancies.6 The 
incremental change in platelet count as corrected for platelet dose that we report also varied by 
indication for transfusion. The smallest incremental change was seen in those at risk of bleeding 
from a device which can be explained by alloimmunization and consumption related to the 
device itself. Surprisingly, children with major bleeding had a greater median rise in platelet 
count than those with minor bleeding or no bleeding. One would expect that the incremental 
change in the more severely bleeding patient would be more modest based on consumption and 
loss in surgical drains. No cold platelets were administered to patients included in this study. It is 
possible that platelets stored at room temperature are relatively inert and are not being consumed 
at a high enough rate to show reduced increments compared to non-bleeding patients. “Cold” 
platelets (stored at 4C) have been shown to have increased hemostatic efficacy and increased 
safety relative to bacterial contamination.7,8,9 Two randomized controlled trials of whole blood 
derived platelets and platelets within whole blood indicate cold storage reduces bleeding and is 
associated with improved platelet function.10,11 Additional trials are being performed that will 
examine the effect of storage temperature of platelets collected by apheresis.12  
Our study confirms that clinicians rely on very few assays, other than total platelet count 
alone, to prescribe platelet transfusions.  Whiting et al13 suggest that viscoelastic testing, such as 
TEG or ROTEM, are more effective than standard lab testing to guide transfusion therapy in 
adults undergoing cardiac surgery or following trauma.  A recent Cochrane review analyzing the 
benefit of viscoelastic testing to monitor hemostatic treatment versus usual care in 17 trials in 
adults or children with bleeding reported that application of TEG- or ROTEM-guided transfusion 
strategies may reduce the need for blood products, and improve morbidity in patients with 
bleeding.14  The PLADO trial comparing different platelet doses recruited adults and children 
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with hematological malignancies, and reported a poor relationship between degree of severity of 
thrombocytopenia and bleeding risk.15 More work needs to be done to understand how to define 
bleeding risk other than by use of isolated platelet counts in critically ill children who are at risk 
of bleeding. 
Given there are few evidence-based guidelines for platelet transfusion in critically ill 
children, it is not surprising that significant variation in prescribing practices exists. Randomized 
trials represent the goal for evidence based practitioners but we must recognize considerable 
challenges undertaking such trials of platelet transfusions in critically ill children, and in a setting 
where validated outcome measures of bleeding are not described. Alternative designs of studies 
such as comparative effectiveness methods need to be considered. Since nearly half of the 
children in this cohort had an underlying oncologic diagnosis, this specific patient population 
should be investigated. Furthermore, children being supported by devices that place them at risk 
for bleeding receive the highest exposure to platelet transfusions with a high mortality. Future 
studies should focus on this population as well. 
This study represents the largest prospective data on platelet transfusions in critically ill 
children reported to date. Since the data was predominantly collected with a waiver of consent, 
the study is without selection bias. Given the number of sites involved globally, the results 
should be externally valid for pediatric intensive care units with platelet transfusions readily 
available in their blood banks. The results of the study, though primarily descriptive in nature, 
provide important preliminary data that identifies at risk patient populations and will facilitate 
the design of randomized controlled trials.  
Some limitations exist. Ideally, in a study examining the use of platelet transfusions as a 
hemostatic agent, some measure of bleeding should be collected. However, since there is no 
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validated bleeding assessment tool in critically ill children, it was not included as an outcome. 
Additionally, data was not collected on transfusion of other hemostatic products, such as plasma 
cryoprecipitate, factor concentrates or antifibrinolytics. The design of the study does not permit 
direct comparison between patients transfused and not transfused with platelets as we were not 
able to collect data on the 16,375 non-transfused patients. The population of critically ill children 
transfused with platelets had increased acuity compared to the general PICU population, in both 
PELOD-2 scores (7 versus 4) and mortality (25% versus 6%).16  
In conclusion, this international point prevalence study demonstrates that the majority of 
platelet transfusions prescribed in the pediatric intensive care unit are given prophylactically to 
non-bleeding children and significant variation in platelet thresholds exists. Studies are needed to 
clarify appropriate indications for platelet transfusion and subsequent responses in critically ill 
children according to their illness, with a particular focus on prophylactic transfusions. 
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Table 1. Demographics of Subjects 
 Major Bleeding 
(n=64) 
Minor Bleeding 
(n=115) 
Risk of Bleeding 
from Device 
(n=79) 
Prophylactic 
Transfusions 
(n=278) 
p-
Values 
Age (yr), median (IQR)  3 (0,11) 4 (0,10) 0 (0,3) 5 (1,11) < 0.001 
Sex (male), n (%) 33 (52%) 66 (57%) 44 (56%) 152 (55%) 0.897 
Weight (kg), median (IQR) 13.7 (5.9,36.5) 16.0 (8.5, 28.5) 6.4 (3.5, 18.8) 19.1 (8.6,38.1) < 0.001 
Days Since Admission, 
median (IQR) 
1 (0,3) 2 (0, 8.8) 5 (2, 13) 2 (0,6) < 0.001 
Mechanical Ventilation, n (%) 48 (75%) 82 (71%) 74 (94%) 141 (51%) < 0.001 
Reason for PICU Admission,  
n (%) 
   Respiratory 
   Septic Shock 
   Hemorrhagic Shock 
   Other Shock 
   Trauma 
   Traumatic Brain Injury 
   Burn 
   Cardiac surgery-bypass 
   Cardiac surgery-no bypass 
   Cardiac – non-surgical 
   Emergency surgery 
   Elective surgery 
   Seizure 
   Encephalopathy 
   Meningitis 
   Renal failure 
   Hepatic failure 
   Post-op liver transplant 
   Other 
 
 
15 (23%) 
4 (6%) 
16 (25%) 
4 (6%) 
4 (6%) 
3 (5%) 
0 (0%) 
14 (22%) 
1 (2%) 
3 (5%) 
4 (6%) 
3 (5%) 
1 (2%) 
6 (9%) 
0 (0%) 
3 (5%) 
3 (5%) 
2 (3%) 
23 (36%) 
 
 
51 (44%) 
22 (19%) 
5 (4%) 
5 (4%) 
7 (6%) 
2 (2%) 
1 (1%) 
17 (15%) 
4 (3%) 
10 (9%) 
1 (1%) 
7 (6%) 
6 (5%) 
15 (13%) 
1 (1%) 
15 (13%) 
8 (7%) 
3 (3%) 
27 (23%) 
 
 
48 (61%) 
9 (11%) 
2 (3%) 
4 (5%) 
1 (1%) 
0 (0%) 
0 (0%) 
13 (16%) 
1 (1%) 
12 (15%) 
3 (4%) 
5 (6%) 
0 (0%) 
4 (5%) 
2 (3%) 
8 (10%) 
2 (3%) 
1 (1%) 
15 (19%) 
 
 
96 (35%) 
85 (31%) 
6 (2%) 
11 (4%) 
2 (1%) 
3 (1%) 
1 (0%) 
21 (8%) 
3 (1%) 
16 (6%) 
6 (2%) 
8 (3%) 
8 (3%) 
16 (6%) 
2 (1%) 
29 (10%) 
13 (5%) 
7 (3%) 
92 (33%) 
 
 
< 0.001 
< 0.001 
< 0.001 
0.810 
0.002 
0.114 
0.731 
0.004 
0.366 
0.047 
0.131 
0.312 
0.181 
0.078 
0.390 
0.371 
0.576 
0.879 
0.026 
PELOD-2 Score prior to 
transfusion, median (IQR) 
7 (5.5, 10.5) 7 (6, 11) 8 (7, 11) 7 (4, 9) 0.001 
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Figure 1. Indications for Platelet Transfusions 
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Figure 2. Change in Platelet Count Following Transfusion By Indication
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Table 2. Outcomes Based on Indication for Platelet Transfusion 
 Major Bleeding 
(n=60) 
Minor Bleeding 
(n=113) 
Risk of Bleeding 
from Device 
(n=75) 
Prophylactic 
Transfusions 
(n=274) 
p-
Values 
PICU Length of Stay (days), 
median (IQR) 
10 (4, 27) 14 (7-27) 25 (12-50) 11.5 (5-26) < 0.001 
Length of Mechanical 
Ventilation (days), median 
(IQR) 
4 (2, 16) 9 (2, 17) 17 (10, 43) 4 (0, 15) < 0.001 
Total platelet dose (mL/kg), 
median (IQR) 
30.9 (13.5, 67.3) 27.3 (10.4, 62.1) 97.7 (40.0-243.0) 28.6 (12.3, 79.8) < 0.001 
Mortality, n (%) 18 (28,1%) 40 (35.4%) 27 (35.1%) 48 (17,3%) < 0.001 
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